Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

The Final Word on a Biotech Stock Rebound. The market has successfully averted a bear market twice in May. That’s bullish, and we think it sets things up for a nice stock rebound here.

Biotech stocks set for a rebound in 2024, analysts say Investors warm up to sector amid stabilizing rates and an uptick in dealmaking Last Updated: Dec. 23, 2023 at 6:50 a.m. ET First Published ...

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

The stock's next level of technical resistance is 9% higher at $79.40, from its current price of $72.80. The relative strength index also suggests the stock is oversold after falling below 30. Vertex ...

However, that all seems to be history this year as biotech stocks have begun to rebound due to a wave of FDA approvals, which started in 2023. In fact, over the last two years, ...

While the stock’s fallen over the last five years, it’s seen a rebound in 2023, posting a 33% gain. ... This is definitely one of the biotech stocks to watch.

Biotech Roundup: 3 Stocks to Watch. Checking in with REGN, INCY, ... REGN) stock is finally on the rebound, after a long-term pullback from its Aug. 27, record high of $1,211.20.

However, the big biotech stock is still down close to 15%. I think Vertex is poised for a rebound. Indeed, I think that it could realistically double your money within the next five years.